BioConvergence Revenue and Competitors
Estimated Revenue & Valuation
- BioConvergence's estimated annual revenue is currently $6.2M per year.
- BioConvergence's estimated revenue per employee is $201,000
Employee Data
- BioConvergence has 31 Employees.
- BioConvergence grew their employee count by -6% last year.
BioConvergence's People
Name | Title | Email/Phone |
---|---|---|
1 | Project Manager & Sr. Technical Services Scientist | Reveal Email/Phone |
BioConvergence Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.6M | 23 | 0% | N/A | N/A |
#2 | $23.5M | 117 | -28% | N/A | N/A |
#3 | $575.7M | 2864 | 2% | N/A | N/A |
#4 | $1.8M | 18 | -10% | $1.5M | N/A |
#5 | $5.8M | 29 | -6% | N/A | N/A |
#6 | $10.7M | 53 | 15% | N/A | N/A |
#7 | $271.4M | 1350 | 4% | N/A | N/A |
#8 | $9.2M | 46 | 10% | N/A | N/A |
#9 | $27760M | 44397 | 4% | N/A | N/A |
#10 | $1.2M | 6 | -54% | N/A | N/A |
What Is BioConvergence?
BioConvergence is now d/b/a Singota Solutions. Please visit the Singota Solutions page for current company information: https://www.linkedin.com/company/Singota-solutions/ BioConvergence is a trusted provider of contract services to the pharmaceutical industry. We provide product development, global GMP supply chain and materials management, QC testing and toxicology, clinical materials manufacturing and packaging solutions, and much more. We move products from the bench to the market with quality, speed, reliability, responsiveness, innovation, and transparency. We grasp the challenges each type of client faces as they progress through development and to the clinic and market.
keywords:N/AN/A
Total Funding
31
Number of Employees
$6.2M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.2M | 31 | 11% | N/A |
#2 | $7.6M | 31 | 7% | N/A |
#3 | $4.5M | 31 | -6% | N/A |
#4 | N/A | 31 | 82% | N/A |
#5 | $4.3M | 31 | -18% | N/A |